Novel regenerative therapies that restore hormone balance

JangoBio is a biotechnology company focused on addressing aging and age-related diseases through innovative regenerative stem cell therapies aimed at restoring hormone balance. The company recognizes that hormonal imbalances, particularly the decline in sex hormones due to aging, significantly contribute to the aging process and the onset of related diseases. To combat this, JangoBio is developing specialized organoids designed to regenerate or replace lost gonadal tissues, thereby enhancing sex hormone production. This approach leverages the complex capabilities of stem cells, which can respond to environmental signals and perform necessary functions to restore hormonal equilibrium, ultimately promoting increased health and longevity.

In addition to its core regenerative therapies, JangoBio has established a multi-phase strategy to support its research and development efforts while generating revenue. This includes subsidiaries like JangoCell, which offers cell biology products and services, and JangoDx, which provides diagnostic testing in both veterinary and medical fields. The company is also advancing its JangoPet division, focusing on biologics for companion animals, particularly aged dogs, and is conducting clinical studies in partnership with regional contract research organizations. As JangoBio transitions its products from research to commercialization, it aims to fund further development of advanced stem cell therapies for both human and animal applications.

United States

JangoBio is developing regenerative therapies to reverse hormone imbalances associated with aging and thereby mitigate the risk of developing a wide range of age-related diseases. Pharmaceutical treatments, such as hormone supplementation, do not address the underlying loss of function, and can have significant side effects.

JangoBio

Company Details